Alkolik Olmayan Yağlı Karaciğer Hastalığının Evrelerinde Enflamasyon Oranlarının (Nötrofil/Lenfosit) ve Hemogram Sonuçlarının Araştırılması

Year 2025, Volume: 26 Issue: 1, 129 - 135, 20.03.2025

Mehmet Ali Gül , Duygu Tozcu Yılmaz , Mustafa Çapraz

https://doi.org/10.69601/meandrosmdj.1614618

Abstract

Giriş: Non-alkolik yağlı karaciğer hastalığı (NAYKH), karaciğerde anormal düzeyde yağ birikimi ve buna eşlik eden enflamasyonla karakterize kronik bir durumdur. Bu çalışmanın amacı NAYKH evrelerinde ve sağlıklı bireylerde NLR'nin tanı değerini araştırmaktır.
Yöntem: NAYKH Evre 1'li 49 NAYKH hasta, NAYKH Evre 2'li 48 hasta, NAYKH Evre 3'lü 52 hasta ve 103 sağlıklı kontrol bireyi içeren retrospektif bir vaka kontrol çalışması olarak yürütüldü. Nötrofil/Lenfosit oranları ve RBC, HGB, HCT, MCHC, MPV, WBC, NEUT#, RDW-CV, BASO%, MCH, LYMPH%, PDW, PCT, NLR, EO%, RDW-SD, MONO%, PLT, MCV değerleri incelendi.
Bulgular: Hastalık evreleri ilerledikçe (G3), MPV değerlerinde anlamlı bir azalma (p=0,005*) ve NLR değerlerinde anlamlı bir artış (p<0,05#) gözlendi. Gruplar arasında RBC (p=0,061), HCT (p=0,097), MCHC (p=0,747), MCV (p>0,05), MCH (p>0,05), PDW (p>0,05), PCT (p>0,05), MONO (p>0,05) ve EO (p>0,05) parametrelerinde istatistiksel olarak anlamlı bir fark bulunmamıştır.
Sonuç: MPV ve NLR, NAYKH'nin ilerlemesini izlemek ve hastaların inflamatuar durumunu değerlendirmek için etkili biyobelirteçler olarak düşünülebilir.

Keywords

Alkole bağlı olmayan yağlı karaciğer hastalığı, Nötrofil lenfosit oranı, Ortalama trombosit hacmi.

Investigation of Inflammation Rates (Neutrophil/Lymphocyte) and Hemogram Results in the Stages of Non-Alcoholic Fatty Liver Disease

Abstract

Introducton: Non-alcoholic fatty liver disease (NAFLD) is a chronic condition characterized by excessive fat accumulation in the liver accompanied by inflammation. This study aims to know the diagnostic value of NLR in stages of NAFLD
Methods: A retrospective case-control study was conducted, including 49 NAFLD patients with NAFLD Grade 1, 48 with NAFLD Grade 2, 52 with NAFLD Grade 3, and 103 healthy control (HC) individuals. Neutrophil/Lymphocyte ratios as well as RBC, HGB, HCT, MCHC, MPV, WBC, MCV, MCH, PLT, RDW-SD, RDW-CV, PDW, PCT, NEUT#, LYMPH%, NLR, MONO%, EO%, BASO% values were examined.
Results: As the disease stages progressed (G3), a significant decrease (p=0.005*) in MPV values and a significant increase (p<0.05#) in NLR values were observed. No statistically significant difference was found between the groups in RBC (p=0.061), HCT (p=0.097), MCHC (p=0.747), MCV (p>0.05), MCH (p>0.05), PDW (p>0.05), PCT (p>0.05), MONO (p>0.05) and EO (p>0.05) parameters.
Conclusion: MPV and NLR may be considered as effective biomarkers for monitoring the progression of NAFLD and evaluating the inflammatory status of patients.

Keywords

Non-Alcoholic Fatty Liver Disease, Neutrophil, Lymphocyte

Ethical Statement

Amasya University Non-Interventional Clinical Research Ethics Committee approval was received for the study.( 2024/144)

References

• 1. Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Frontiers in medicine. 2020;7:448. Epub 2020/09/26. doi: 10.3389/fmed.2020.00448. PubMed PMID: 32974366; PubMed Central PMCID: PMCPMC7468507.
• 2. Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287-95. Epub 2023/04/12. doi: 10.1016/j.jhep.2023.03.040. PubMed PMID: 37040843.
• 3. Manikat R, Ahmed A, Kim D. Up-to-date global epidemiology of nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2023;12(6):956-9. Epub 2023/12/20. doi: 10.21037/hbsn-23-548. PubMed PMID: 38115930; PubMed Central PMCID: PMCPMC10727827.
• 4. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18(3):245-50. Epub 2018/06/03. doi: 10.7861/clinmedicine.18-3-245. PubMed PMID: 29858436; PubMed Central PMCID: PMCPMC6334080.
• 5. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121-40. Epub 2016/04/08. doi: 10.1007/s00125-016-3902-y. PubMed PMID: 27053230.
• 6. Kopec KL, Burns D. Nonalcoholic Fatty Liver Disease: A Review of the Spectrum of Disease, Diagnosis, and Therapy. Nutr Clin Pract. 2011;26(5):565-76. doi: 10.1177/0884533611419668. PubMed PMID: WOS:000295222800008.
• 7. Zhu N, Wang X, Zhu H, Zheng Y. Blood cell parameters and risk of nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study. BMC Med Genomics. 2024;17(1):102. Epub 2024/04/24. doi: 10.1186/s12920-024-01879-7. PubMed PMID: 38654378; PubMed Central PMCID: PMCPMC11040836.
• 8. Miele L, Alberelli MA, Martini M, Liguori A, Marrone G, Cocomazzi A, et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res. 2021;231:24-38. Epub 2020/11/11. doi: 10.1016/j.trsl.2020.11.003. PubMed PMID: 33171266.
• 9. Solak Y, Yilmaz MI, Sonmez A, Saglam M, Cakir E, Unal HU, et al. Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(4):532-40. doi: 10.1007/s10157-012-0728-x. PubMed PMID: WOS:000323511000008.
• 10. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clinical Medicine. 2018;18(3):245-50. doi: https://doi.org/10.7861/clinmedicine.18-3-245.
• 11. Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66(2):323. doi: 10.1136/gutjnl-2016-311854.
• 12. Asil M, Dertli R. The Neutrophil-to-Lymphocyte Ratio as A Noninvasive Marker in Patients with Biopsy-Proven Non-Alcoholic Steatohepatitis. Istanb Med J. 2016;17(4):131-5. doi: 10.5152/imj.2016.74755. PubMed PMID: WOS:000391011900004.
• 13. Lesmana CRA, Kencana Y, Rinaldi I, Kurniawan J, Hasan I, Sulaiman AS, et al. Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). Diabet Metab Synd Ob. 2022;15:15-22. doi: 10.2147/Dmso.S330526. PubMed PMID: WOS:000742778300003.
• 14. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. Bmc Medicine. 2017;15. doi:10.1186/s12916-017-0806-8. PubMed PMID: WOS:000396072300001.
• 15. Akdas S, Yazihan N. From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential. Hepatology forum. 2024;5(3):126-38. Epub 2024/07/15. doi: 10.14744/hf.2023.2023.0042. PubMed PMID: 39006144; PubMed Central PMCID: PMCPMC11237240.
• 16. Shavakhi M, Nourigheimasi S, Dioso E, Goutnik M, Lucke-Wold B, Khanzadeh S, et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology. 2022;2022(1):1554079. doi: https://doi.org/10.1155/2022/1554079.
• 17. Abdel-Razik A, Mousa N, Shabana W, Refaey M, ElMahdy Y, Elhelaly R, et al. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study. Eur J Gastroenterol Hepatol. 2016;28(1):e1-9. Epub 2015/10/16. doi: 10.1097/meg.0000000000000486. PubMed PMID: 26469357.
• 18. WenYi J, Ting Q, PiaoPiao Y, JinMing W. Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2022;33(1):53-61. Epub 2022/01/19. doi: 10.5152/tjg.2022.20715. PubMed PMID: 35040788; PubMed Central PMCID: PMCPMC9128444.
• 19. Kara M, Dogru T, Genc H, Sertoglu E, Celebi G, Gurel H, et al. Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27(10):1144-8. Epub 2015/06/11. doi: 10.1097/meg.0000000000000405. PubMed PMID: 26062078.
• 20. Acar, T., Adibelli, Z. H. (2017). Nötrofil/Lenfosit Oranının Abdominal Yağ Dağılımı, Karaciğer Yağlanması ve Karaciğer Hacmine Olan Etkisi. Konuralp Tip Dergisi, 9(2),73-77.
• 21. Wang Y, Guo S, He Y, Zhang Q, Zhou N, Wang D, et al. Relationship between Neutrophil-to-Lymphocyte Ratio and Liver Fibrosis in Nonalcoholic Fatty Liver Disease Among Adults in the United States: Data from the National Health and Nutrition Examination Survey 2017-2018. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2024;35(4):335-42. Epub 2024/08/11. doi: 10.5152/tjg.2024.23231. PubMed PMID: 39128078; PubMed Central PMCID: PMCPMC11114246.
• 22. Duan Y, Luo J, Pan X, Wei J, Xiao X, Li J, et al. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children. Frontiers in Public Health. 2022;10. doi: 10.3389/fpubh.2022.991393.
• 23. Karaoğullarindan Ü, Üsküdar O, Odabaş E, Saday M, Akkuş G, Delik A, et al. Is mean platelet volume a simple marker of non-alcoholic fatty liver disease? Indian Journal of Gastroenterology. 2023;42(2):219-25. doi: 10.1007/s12664-022-01330-8.
• 24. Kocabay G, Karabay CY, Kalayci A, Colak Y. Mean platelet volume in patients with non-alcoholic fatty liver disease: is mean platelet volume ready as a surrogate marker? Clinical Chemistry and Laboratory Medicine (CCLM). 2014;52(11):e249-e52. doi: doi:10.1515/cclm-2014-0303.
• 25. Alvarez L, Cipher D, Weideman RA, Brown G. Mean platelet volumes in non-alcoholic liver disease (NAFLD): is there a relationship to cardiovascular events? Gastroenterology & Hepatology. 2016;5(5):325-9. doi: 10.15406/ghoa.2016.05.00157.